In lung cancer, this upregulation of PD-L1 was associated with an adverse clinical outcome [96], while in some other cancers (e.g., ESCC), PD-L1 activation following chemotherapy had no impact on patients’ outcomes [98]. Here, CD274 is linked to lung carcinoma.